Articles related to OBESITY AND WEIGHT MANAGEMENT

Whether prescribing them for diabetes or weight loss, what factors should you consider when choosing among the seven approved GLP-1 agonist formulations? This concise review highlights the variables.

Sibutramine, a serotonin, norepinephrine, and dopamine reuptake inhibitor, can cause an increase in heart rate and blood pressure that may place individuals with cardiovascular disease at risk.

In this phase 3 double-blind, randomized, 72-week controlled trial of 2,539 adults with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.

Fast-tracked tirzepatide is looking to join the diabetes-turned-obesity drug market. Additional options in the class could be a boon to patients, given the persisting semiglutide shortage.

The updated ADA standards have several significant changes. These include: A revised definition of HTN to match that of the ACC and AHA New recommendations for statin use Changes to recommendations around CKD treatment Revised weight loss goals Use of diabetes technology And much more

The combined analysis showed that therapist-led CBT, lisdexamfetamine, SGAs, and topiramate reduced binge eating and related obsessions and compulsions. Lisdexamfetamine and topiramate reduced weight. SGAs reduced symptoms of depression.